Description
DigiPharm (operating as Digipharm Ltd in the UK, DigiPharm GCC in Saudi Arabia, and DigiPharm Switzerland GmbH) is an independent commercial specialist organisation focused on transforming how healthcare is commissioned, paid for, and delivered. Its core product, REIMBURSE® (protected by U.S. Patent no. 12020825), is a Value-Based Procurement platform that uses AI and blockchain-based smart contracts to align payments with proven health outcomes, reduce administrative burden, and support outcome-based and managed-entry agreements for pharmaceuticals, medical devices, diagnostics, robotics, digital therapeutics and services. Its companion platform, DigiHealth®, is a patient-centric ecosystem that collects and analyses patient-reported outcome and experience measures (PROMs/PREMs) to support clinical evaluation, market access negotiations, HTA submissions and research, rewarding patients with the DGH token (an FINMA-regulated Swiss ERC-20 token on Ethereum) for surveys, health data sharing and healthy activities. DigiPharm serves healthcare payers and providers, pharmaceutical and medical device manufacturers, service providers, and patients/the public, positioning itself as a neutral, independent facilitator of value-based healthcare transactions.